Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.
Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.
复制标题
p15 在一系列 spitzoid 黑素细胞肿瘤中的表达。
DOI：
10.1111/cup.13424
复制
发表时间：
2019
影响因子：
1.7
通讯作者：
Chu,EmilyY
中科院分区：
文献类型：
--
作者：
Ma,SophiaA;O'Day,ConorP;Dentchev,Tzvete;Takeshita,Junko;Ridky,ToddW;Seykora,JohnT;Chu,EmilyY
由于Spitz痣、非典型Spitz肿瘤（ast）和Spitz样黑素瘤之间的临床和组织病理学特征重叠，Spitz样黑素瘤很难准确分类。p16 （CDKN2A）的表达已被用作spitzo样病变的标志物。然而，它的表达式可能是可变的。p15是一种由cdkn2b编码的肿瘤抑制因子，其缺失最近被证明可促进从痣到黑色素瘤的转变。我们试图确定p15是否是区分Spitz痣和Spitz样黑素瘤的有效免疫组织化学标志物，并比较p15和p16在该人群中的染色情况。方法对Spitz痣（n = 19）、ast （n = 41）和Spitz样黑色素瘤（n = 17）进行p15和p16的免疫组化检测。免疫表达按四级系统分类：0（阴性）、1+（弱）、2+（中等）、3+（强）。结果3+/强p15染色在Spitz痣中占68.4%，在ast中占34.2%，在Spitz样黑色素瘤中占17.7%。相比之下，我们观察到3+ p16染色在Spitz痣（57.9%）、ast（56.1%）和Spitz样黑色素瘤（58.8%）中所占比例大致相当。结论这些数据表明p15可能比p16更有助于区分良性和恶性spitzoid病变的生物标志物。
BackgroundAccurate classification of spitzoid melanocytic lesions is difficult due to overlapping clinical and histopathologic features between Spitz nevi, atypical Spitz tumors (ASTs), and spitzoid melanomas. Expression of p16 (CDKN2A) has been used as a marker of spitzoid lesions. However, its expression may be variable. p15 is a tumor suppressor encoded byCDKN2B, loss of which has been recently shown to promote transition from nevus to melanoma. We sought to determine whether p15 is a useful immunohistochemical marker to distinguish Spitz nevi from spitzoid melanomas and to compare p15 and p16 staining in this population.MethodsImmunohistochemistry for p15 and p16 was performed on Spitz nevi (n = 19), ASTs (n = 41), and spitzoid melanomas (n = 17). Immunoexpression was categorized by a four‐tiered system: 0 (negative), 1+ (weak), 2+ (moderate), 3+ (strong).Results3+/strong p15 staining was observed in 68.4% of Spitz nevi, 34.2% of ASTs, and 17.7% of spitzoid melanomas. By contrast, we observed 3+ p16 staining in roughly equivalent percentages of Spitz nevi (57.9%), ASTs (56.1%), and spitzoid melanomas (58.8%).ConclusionThese data illustrate that p15 may be more useful than p16 as a biomarker to help distinguish benign from malignant spitzoid lesions.